Latest Breaking News On - Algernon pharmaceuticals inc - Page 2 : comparemela.com

Algernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltx

Algernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltx
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Christopher moreauDietrich stephanMarket researchSeyltx incDrug administrationAlgernon pharmaceuticals incAlgernon pharmaceuticalsBridge market research

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD - Algernon Pharmaceuticals (OTC:AGNPF)

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) a Canadian clinical stage pharmaceutical development

United statesUnited kingdomBritish columbiaChristopherj moreauAlgernon pharmaceuticalsCompany or algernonChinese patent officeAlgernon pharmaceuticals incAlgernon neuroscience

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

British columbiaUnited kingdomUnited statesChristopherj moreauNo securities exchangeAlgernon pharmaceuticalsCanadian securities exchangeChristopherj moreauceoalgernon pharmaceuticals incCompany or algernonAlgernon pharmaceuticals incNeither the canadian securities exchangeChinese patent officeAlgernon neurosciencePharmaceuticals incMarket regulator

Algernon Pharmaceuticals Inc Reports Earnings Results for the First Quarter Ended November 30, 2023

Algernon Pharmaceuticals Inc. reported earnings results for the first quarter ended November 30, 2023. For the first quarter, the company reported net loss was CAD 0.521554 million compared to CAD.

Algernon pharmaceuticals incAlgernon pharmaceuticals

Algernon Pharmaceuticals Inc Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc. announced that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for.

Algernon pharmaceuticals incJapanese patent officeAlgernon pharmaceuticalsTreating idiopathic pulmonary fibrosis